Current reports
Filing Types
BioNTech SE
Companies

58 filings

Newest first
Filter options loading...
Top filers
Top filing types
Recent filing years
6-K
BNTX BioNTech SE
20 Nov 20
Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
6-K
BNTX BioNTech SE
18 Nov 20
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
6-K
BNTX BioNTech SE
12 Nov 20
Interim Condensed Consolidated Financial Statements
6-K
BNTX BioNTech SE
10 Nov 20
BioNTech Announces Third Quarter 2020 Financial Results and Corporate Progress
6-K
BNTX BioNTech SE
10 Nov 20
Current report (foreign)
6-K
BNTX BioNTech SE
9 Nov 20
Current report (foreign)
6-K
BNTX BioNTech SE
9 Nov 20
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
6-K
BNTX BioNTech SE
16 Oct 20
Current report (foreign)
6-K
BNTX BioNTech SE
6 Oct 20
Current report (foreign)
6-K
BNTX BioNTech SE
17 Sep 20
BioNTech to Acquire GMP Manufacturing Site to Expand COVID-19 Vaccine Production Capacity in First Half 2021
6-K
BNTX BioNTech SE
15 Sep 20
BioNTech to Receive up to €375M in Funding from German Federal Ministry of Education and Research to Support COVID-19 Vaccine Program BNT162
6-K
BNTX BioNTech SE
14 Sep 20
Current report (foreign)
6-K
BNTX BioNTech SE
9 Sep 20
Pfizer and BioNTech Announce Data From
6-K
BNTX BioNTech SE
9 Sep 20
Current report (foreign)
6-K
BNTX BioNTech SE
21 Aug 20
Current report (foreign)
6-K
BNTX BioNTech SE
18 Aug 20
Current report (foreign)
6-K
BNTX BioNTech SE
12 Aug 20
Current report (foreign)
6-K
BNTX BioNTech SE
11 Aug 20
BioNTech Announces Second Quarter 2020 Financial Results and Corporate Progress
6-K
BNTX BioNTech SE
5 Aug 20
Supply to be provided over the course of 2021, subject to Health Canada approval
6-K
BNTX BioNTech SE
5 Aug 20
BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China